Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Ponatinib versus Imatinib in Newly Diagnosed Chronic-Phase CML
KCT0000562Phase 3Terminated
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ponatinib in chronic myelogenous leukemia (CML), sponsored by ARIAD Pharmaceuticals, Inc.. Started Oct 2012; status: terminated.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on KCT0000562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000562.